Jump to page content

Board of Directors

The Berlin Institute of Health at Charité (BIH) is led by a Board of Directors, responsible for strategic planning and implementation of the research program.

Board Members

  • Prof. Dr. Christopher Baum

    Chairman of the Board of Directors of the BIH at Charité and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin

  • Dr. Michael Frieser

    Administrative Director of the BIH at Charité

Professor Christopher Baum is the Chairman of the Board of Directors of the BIH. More information about Professor Baum can be found in his curriculum vitae.

Extended Board of Directors

In order to include the full-time scientific staff of the translational research area in the opinion-forming and decision-making of the directorate, an extended board of directors is formed. The extended board of directors advises the voting members of the board of directors with regard to its tasks. For this purpose, it may submit statements to the voting members and request information as well as the treatment of its motions.

The Extended Board of Directors consists of:

  • Professor Axel R. Pries (Dean)
  • four elected persons belonging to the full-time scientific staff of the Translational Research Unit.

The members will be announced shortly.

Governing Board

All activities of BIH are supervised by the Supervisory Board, which is also responsible for approving essential decisions such as the business plan, strategic planning, appointments, and investments.

Deputies of the German Government
Deputies of the German Government  
State Secretary Christian Luft Federal Ministry of Education and Research, Chair
Deputies of the federal state of Berlin
Deputies of the federal state of Berlin  
State Secretary Steffen Krach Office of The Senate for Science, Deputy Chair
External experts
External experts  
Prof. Monika Jungbauer Gans Scientific management, German Centre for Higher Education Research and Science Studies (DZHW)
Prof. Blanche Schwappach-Pignataro Dean, Medical Center Hamburg-Eppendorf (UKE)
Dr. Christian Rommel Head of Research and Development, Division Pharmaceuticals, BAYER AG
Annette Schavan Federal Minister a. D.

Scientific Advisory Board

The Scientific Advisory Board is responsible for providing the Executive Board and Supervisory Board with external specialized knowledge regarding future important research topics and ongoing scientific and strategic issues; it meets every six months. At present the Scientific Advisory Board consists of thirteen international experts in translational research and systems medicine.

Chair of the Scientific Advisory Board

Prof. Lina Badimon
Institute for Cardiovascular Science, Barcelona, Spain

Vice Chair

Dr. André Terzic
Mayo Clinic, USA

Members of the Scientific Advisory Board
Name Institution
Lina Badimon IR-Hospital Sta. Creu i S. Pau, Spain
Prof. Roland Lauster TU Berlin, Germany
Prof. Teri Manolio National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Prof. Miriam Merad Mount Sinai School of Medicine, New York
Prof. David Moher Ottawa Hospital Research Institute, Canada
Prof. Maritta Perälä-Heape University of Oulu, Finland
Prof. Aviv Regev Head of Genentech and Early Development, Roche, USA
Prof. Claudia Schmidtke Herzzentrum Bad Segeberg, Patientenbeauftragte der Bundesregierung, Germany
Prof. Alan R. Shuldiner University of Maryland School of Medicine, Baltimore, USA
André Terzic Mayo Clinic, USA
Prof. Fabian Theis Helmholtz Zentrum München, Germany
Prof. David A. Williams Chief, Division of Hematology/Oncology, Boston Children’s Hospital / Harvard Medical School, USA
N. N. N. N.
N. N. N. N.